Abstract
Objective: The research aims to enhance poorly water-soluble drug Simvastatin (SMV) solubility and bioavailability by solid dispersion (SD) using various sugar carriers like lactulose, xylitol, Sorbitol, and soluplus.
Methods: First, the drug was subjected to determine bulk density, carr’s index, Hausner’s ratio, angle of repose, solubility analysis in various solvents like 0.1 N HCl, 6.8pH, 7.2pH phosphate buffers, methanol, and ethanol and preformulation studies. via various carrier concentrations (1:0.5, 1:1, 1:1.5, 1:2, and 1:3), SMV solid dispersions (SD s) were made by solvent evaporation and fusion. The various physiochemical parameters of each formulation were tested.
Results: For various physicochemical criteria, all of the formulations were found to be within the allowed pharmacopoeial limits. Preformulation studies such as FT-IR demonstrated the lack of interactions between drugs and excipients. In comparison to the other solvents, 0.1N HCl showed SMV to be more soluble. The SDs underwent yield, entrapment, and in vitro drug release study evaluations. 88 to 100.68% recovery rates and 92 to 101% capture efficiency were observed. While SDs containing Sorbitol released 74-98% of the medicine, formulations utilizing Sorbitol demonstrated 80-99% drug release, and formulations using xylitol as a carrier released 83-99% of the drug. For more than 60 min, the formulation, including lactulose, delivered 91-100% of the Simvastatin dose.
Conclusion: Lactulose-containing SMV SDs demonstrated superior release characteristics, and an optimized formulation with a 1:1.5 drug-to-carrier ratio has been chosen.
Publisher
Innovare Academic Sciences Pvt Ltd
Reference34 articles.
1. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G. Development of self-micro emulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 2004 Apr 15;274(1-2):65-73. doi: 10.1016/j.ijpharm.2003.12.028, PMID 15072783.
2. McClelland GA, Stubbs RJ, Fix JA, Pogany SA, Zentner GM. Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form. Pharm Res. 1991 Jul;8(7):873-6. doi: 10.1023/a:1015899328105, PMID 1924137.
3. Cheng H, Sutton SC, Pipkin JD, Zentner GM, Rogers JD, Schwartz JI. Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans. Pharm Res. 1993;10(11):1683-7. doi: 10.1023/a:1018997308946, PMID 8290485.
4. USP 24/NF, USP Convention, Rockville; 2000. p. 1942.
5. Bolourchian N, Mahboobian MM, Dadashzadeh S. The effect of PEG molecular weights on dissolution behavior of simvastatin in solid dispersions. Iran J Pharm Res. 2013;12 Suppl:11-20. PMID 24250667.